Publications

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma

A Phase I Study of the First-in-Class Antimitochondrial
Metabolism Agent,CPI-613, in Patients with Advanced
Hematologic Malignancies

Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy

A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo